Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes

Condition(s) studied

Investigational drug(s) / intervention(s)

Pacemaker implantation: Pacemaker implantation methods include right ventricular pacing, biventricular pacing, conduction system pacing

Study summary

Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods.

This study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.

Eligibility

Primary outcome measure(s)

• Tricuspid regurgitation progression（Progression of tricuspid regurgitation ≥ grade 0.5） — Mean follow-up of 1 year
  Grading of tricuspid regurgitation severity:Grade 0: None Grade 0.5: Trace Grade 1: Mild Grade 1.5: Mild to moderate Grade 2: Moderate Grade 2.5: Moderate to severe Grade 3: Severe

Trial sites (1)

More Haiyan Wang trials in China

Other trials for the same condition